Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353942 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| SCHEMBL352795 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL248092 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL913942 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL913941 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Ammonia Solution, Strong SCHEMBL4826153 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| SCHEMBL30913865 | 0.94 | CA12 (0.53) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| SCHEMBL20303794 | 0.89 | L3MBTL1 (0.58) | ALDH1A1HSD17B10MAPTTSHRMAPK1 | |
| SCHEMBL21774543 | 0.89 | L3MBTL1 (0.58) | ALDH1A1HSD17B10MAPTTSHRMAPK1 | |
| SCHEMBL11813645 | 0.88 | LOXL2 (0.70) | ALDH1A1HSD17B10ACHEMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121431735-B | Characterization method of molecular weight and molecular weight distribution of crystalline polyaryletherketone | 吉林大学 | 2026-05-19 | — | — | CN | claimed |
| US-20240350609-A1 | METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2024-10-24 | — | — | US | claimed |
| EP-4450082-A1 | METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF | Serum Institute Of India Private Limited (IN) | 2024-10-23 | — | — | EP | claimed |
| CN-118806889-A | Method for improving adsorption of polysaccharide-protein conjugates and multivalent vaccine formulations obtained therefrom | 印度血清研究所私人有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118084733-A | Preparation method of key intermediate for synthesizing tubulin inhibitor | 重庆皓元生物制药有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-107619432-B | Glycopeptide derivative and pharmaceutically acceptable salt, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2023-03-17 | — | — | CN | claimed |
| CN-112079724-B | Preparation method of dehydroxy mirabegron and intermediate thereof | 南京易亨制药有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-115068587-A | Glycopeptide compound with antiviral activity and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2022-09-20 | — | — | CN | claimed |
| EP-4025246-A2 | IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF | Serum Institute Of India Private Limited (IN) | 2022-07-13 | — | — | EP | claimed |
| CN-114728053-A | Immunogenic compositions against intestinal disease and process for preparing same | 印度血清研究所私人有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-1999036086-A1 | LIPOOLIGOSACCHARIDE-BASED VACCINE FOR PREVENTION OF MORAXELLA (BRANHAMELLA) CATARRHALIS INFECTIONS IN MAMMALS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-07-22 | — | — | WO | claimed |
| WO-1998026799-A1 | CONJUGATE VACCINE FOR SALMONELLA PARATYPHI A | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-25 | — | — | WO | claimed |
| EP-0433897-B1 | Process for preparing an optically active cyclobutane nucleoside | SQUIBB & SONS INC (US) | 1997-10-01 | — | — | EP | claimed |
| EP-0508307-B1 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL CO (JP) | 1995-11-29 | — | — | EP | claimed |
| US-5288900-A | Crystallization of optical isomers of leukotriene antagonists using (R)-4-nitro-α-methylbenezenemethonamine | SMITHKLINE BEECHAM CORPORATION (US) | 1994-02-22 | — | — | US | claimed |
| EP-0552254-A1 | CRYSTALLIZATION OF OPTICAL ISOMERS OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-28 | — | — | EP | claimed |
| EP-0508307-A2 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-14 | — | — | EP | claimed |
| WO-1992005151-A1 | CRYSTALLIZATION OF OPTICAL ISOMERS OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-04-02 | — | — | WO | claimed |
| US-5064961-A | PROCESS FOR PREPARING AN OPTICALLY ACTIVE CYCLOBUTANE NUCLEOSIDE | E. R. SQUIBB & SONS, INC. (US) | 1991-11-12 | — | — | US | claimed |
| EP-0433897-A2 | Process for preparing an optically active cyclobutane nucleoside | E.R. SQUIBB & SONS, INC. (US) | 1991-06-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350609-A1 | METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF | DDOST, CD14, STT3B | ALDH1A1 4882/4885HSD17B10 4071/4885ACHE 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.